Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NCM – Real Time Price. Currency in USD

9.60

+0.09 (0.95%)

Market open: Aug 12, 2026, 12:54 PM EDT

9.70

+0.19 (2.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

04.08.2026

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Dose-finding Phase 1b study (n=240) on track for topline data in September 2026 CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1 class CRB-913 yielded 15 times lower brain penetration than monlunabant in mice NORWOOD, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the last patient has completed their last clinical visit (“Last Patient Last Visit”) in the Company's CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity.

Videos

No Data

There is no data to display

Press releases

04.08.2026

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Videos

No Data

Press releases

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Videos

No Data

Press releases

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Search stocks

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Videos

No Data

Press releases

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Videos

No Data

Press releases

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity